call 1800 257 600 email [email protected]

Clinical Trials

Cancer Type

State

Phase

Treatment

Inhibitor

Investigating the impact of adding olaparib, or olaparib and durvalumab together, to standard chemotherapy before surgery in young, pre-menopausal women with HER2-negative breast cancer.

ACTRN 12623000657628 Brief Summary This study aims to find out if adding…

Read more arrow_forward

Investigation of the safety and efficacy of irreversible electroporation (IRE) using the NanoKnife® System in patients with unresectable stage 3 pancreatic cancer who have received 3 months of chemotherapy (DIRECT/InspIRE Australia)

ACTRN 12621000955819 Brief Summary The aim of this study is to investigate…

Read more arrow_forward

Isatuximab in Combination With Novel Agents in RRMM – Master Protocol

NCT 04643002 Brief Summary The purpose of this umbrella study is to…

Read more arrow_forward

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation (PyramIDH)

NCT 06465953 Brief Summary This study will enroll participants with myelodysplastic syndromes…

Read more arrow_forward

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)

NCT 06127407 Brief Summary Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind,…

Read more arrow_forward

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT 06501625 Brief Summary The objective of this study is to investigate…

Read more arrow_forward

KARPOS – A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme

ACTRN 12622001514796 Brief Summary The aim of this study is to assess…

Read more arrow_forward

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

NCT 03662126 Brief Summary This study evaluates KRT-232, a novel oral small…

Read more arrow_forward

KS014 in Advanced Solid Tumors That Express HER2

NCT 05872295 Brief Summary This study will evaluate the recommended dose for…

Read more arrow_forward

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT 03486873 Brief Summary The purpose of this study is to…

Read more arrow_forward

Knowledge Base

Cancer Types Cancer Services Health Professionals Clinical Trials

How we help you

Our support knows no limits, which means we do whatever it takes to be there for all you need.

How we help you View the Rare Cancer Support Guide

Can’t find what you’re looking for?

We have a friendly team available to chat about any questions you may have, or just to lend an ear if you’re having a tough time.

Call 1800 257 600 Have us call you